<DOC>
	<DOCNO>NCT00196768</DOCNO>
	<brief_summary>Summary Acute promyelocytic leukemia define characteristic morphology ( AML FAB M3/M3v ) , specific translocation ( 15 ; 17 ) molecular correlate ( PML/RARa RARa/PML ) . Thereby separate form acute leukemia . By all-trans retinoic acid combination chemotherapy cure rate 70 80 % reach . On average , 10 % patient still die early phase treatment 20 30 % relapse . Molecular monitoring minimal residual disease ( MRD ) qualitative nest RT-PCR quantitative REAL-time PCR PML/RARa allow follow individual kinetics MRD identify patient imminent hematological relapse . A standardized treatment patient relapse APL yet establish . With arsenic trioxide ( ATO ) monotherapy remission rate 80 % achieve long-lasting molecular remission describe . The drug mostly well tolerate . ATO exert dose dependent dual effect APL blast , apoptosis higher partial differentiation low concentration . ATO also successfully administer allogeneic autologous transplantation . ATO approve treatment relapse refractory APL Europe USA . In present protocol , ATO give remission induction : 1. patient hematological molecular first subsequent relapse APL 2. patient reach hematological molecular remission first line therapy . Induction therapy ATO mandatory part protocol . After remission induction , several option postremission therapy . Factors influence treatment decision individual case : 1. eligibility allogeneic transplantation 2. eligibility autologous transplantation 3. presence absence contraindication intensive chemotherapy 4. PCR status induction follow ( RT-PCR PML/RARa , sensitivity 10-4 ) A mandatory form post-remission therapy define protocol . Data outcomes post-remission therapy document order collect data treatment ATO . The following stratification post-remission therapy perform accord decision treat physician : Patients HLA-compatible donor suitable allogeneic stem cell transplantation transplant . In patient positive PCR one cycle intensive chemotherapy ( HAM ) transplantation consider patient negative result immediately transplant without precede chemotherapy . In patient qualify allogeneic , autologous transplantation , intensity chemotherapy ( Ara-C dose HAM cycle ) schedule accord PCR status ATO patient 's age . In patient 60 year , recommend single Ara-C dose schedule 3 g/m² case positive PCR result 1 g/m² case negative PCR result ATO . In patient age 60 year , Ara-C dose uniformly reduce 1 g/m² independent PCR status . Patients eligible allogeneic autologous transplantation ( old , stem cell collect , PCR positive stem cell transplant , contraindication intensive chemotherapy ) receive three cycle ATO ATRA . The group patient qualify autologous transplantation , without contraindication intensive chemotherapy receive age adapt HAM , whenever positive PCR persist reappears three maintenance cycle ATO . A close monitoring PCR PML/RARa treatment cycle part protocol . The main objective protocol take advantage expect low toxicity ATO keep part chemotherapy low possible .</brief_summary>
	<brief_title>Treatment Protocol Relapsed Acute Promyelocytic Leukemia ( APL ) With Arsenic</brief_title>
	<detailed_description>Synopsis Title study Treatment acute promyelocytic leukemia ( APL ) arsenic trioxide ( ATO ) . A phase-IV study ass effectiveness toxicity ATO well kinetics minimal residual disease ( MRD ) patient first subsequent hematological molecular relapse APL . Study coordination : Priv.-Doz . Dr. Eva Lengfelder Protocol committee : German AMLCG German AML-Intergroup ( open participate group ) Study duration : Time recruitment 3 year , individual follow schedule 3 year Objectives study Primary objective Assessment : 1. rate hematological remission 2. rate molecular remission 3. kinetics MRD PML/RARa ATO Secondary objective Assessment : 1. side effect ATO 2. percentage transplantable patient comparison historical result chemotherapy 3. overall survival 4. duration hematological molecular remission Study characteristic : Open-label multicenter control phase-IV study Number patient : 30 patient Inclusion criterion * Patients first subsequent hematological molecular relapse APL * Persistence positive PCR hematological CR first line therapy * No complete hematological remission first line therapy * Age 18 year * No upper age limit * Informed consent patient Exclusion criterion * Absolute QTc-interval prolong 460 msec therapy ( normal electrolyte , drug prolong QT-interval ) * Heart failure NYHA grade III IV * Renal hepatic failure WHO grade &gt; = III * Pneumonia hypoxemia * Uncontrolled sepsis * Pregnancy lactation period - Secondary malignancy , major influence prognosis - Expected noncompliance - No informed consent patient Diagnostic measure : Confirmation relapse RT-PCR PML/RARa cytogenetics . Follow PCRs quantitative nest RT-PCR qualitative REAL-time PCR PML/RARa . Treatment plan Induction therapy : - 3 cycle ATO aim induce hematological molecular remission . Options postremission therapy : · Allogeneic transplantation ( PBSCT ) suitable patient relate unrelated donor . The administration chemotherapy precede allogeneic transplantation stratify accord PCR status ATO . Chemotherapy ( HAM ) consider PCR positive patient accord individual situation . No chemotherapy give PCR negative patient . · Autologous PBSCT patient without donor qualify autologous transplantation . The intensity chemotherapy ( HAM either 3 1 g/m² ) propose accord PCR status PML/RARa ( sensitivity 10-4 ) ATO patient 's age . · 3 maintenance cycle ATO . This follow HAM patient persistence reappearance positive PCR . Patients eligible allogeneic autologous transplantation , without contraindication intensive chemotherapy . · 3 maintenance cycle ATO patient eligible allogeneic autologous transplantation ( suitable donor , old , stem cell collect , positive stem cell transplant ) contraindication intensive chemotherapy . Monitoring MRD mandatory ATO cycle treatment step . ( Details treatment plan show overview study design , Paragraph 2.2 ) . Criteria evaluation The effectiveness therapy assess evaluation rate hematological molecular remission duration remission accord commonly use definition . The safety therapy assess close study monitoring use criterion toxicity accord WHO .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Patients first subsequent hematological molecular relapse APL Persistence positive PCR hematological complete remission ( CR ) first line therapy No complete hematological remission first line therapy Age 18 year No upper age limit Informed consent patient Absolute QTcinterval prolong 460 msec therapy ( normal electrolyte , drug prolong QTinterval ) Heart failure New York Health Association grade III IV Renal hepatic failure World Health Organization grade &gt; = III Pneumonia hypoxemia Uncontrolled sepsis Pregnancy lactation period Secondary malignancy , major influence prognosis Expected noncompliance No informed consent patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>relapse</keyword>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>arsenic</keyword>
</DOC>